Explore the Global Biologics Contract Manufacturing Market— analysis of key trends, regional growth, top players, and a 10-year forecast from 2026 to 2036.

Future Market Insights

Biologics Contract Manufacturing Market

Key Insight

Biologics contract manufacturing sales will expand through 2036, with monoclonal antibodies holding 25.3% of the product type segment in 2026, driven by expanding biologic drug pipelines and increasing outsourcing by biopharma companies. The market was valued at USD 35.20 billion in 2025 and is expected to be worth USD 103.48 billion by 2036.

May 13, 2026

Anurag Sharma

250 Pages

Cite this Report

Biologics Contract Manufacturing Market

https://www.futuremarketinsights.com/reports/biologics-contract-manufacturing-market

License

Buy Now

Summary ToC Infographics Companies

Key Players

The Vanguard Group
Boehringer Ingelheim International GmbH
Catalent Inc
Eurofins Scientific
FUJIFILM Diosynth Biotechnologies Limited
Lonza
Samsung Biologics
Thermo Fisher Scientific Inc.
WuXi Biologics

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Biologics Contract Manufacturing Market

Key Players

Similar Industry Reports